Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions

被引:80
作者
Watson, AMD
Lambert, GW
Smith, KJ
May, CN [1 ]
机构
[1] Univ Melbourne, Howard Florey Inst, Melbourne, Vic 3010, Australia
[2] Baker Heart Res Inst, Melbourne, Vic, Australia
关键词
cardiac output; adrenocorticotropic hormone; glucose; hemodynamics; urotensin; sheep;
D O I
10.1161/01.HYP.0000084633.85427.E6
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Urotensin II is a small peptide whose receptor was recently identified in mammals as the orphan G protein - coupled receptor-14. The reported cardiovascular responses to systemic urotensin II administration are variable, and there is little detailed information on its central cardiovascular actions. We examined the cardiovascular and humoral actions of intracerebroventricular urotensin II (0.02 and 0.2 nmol/kg and vehicle) and intravenous urotensin II ( 2, 20, and 40 nmol/kg and vehicle) in conscious ewes previously surgically implanted with flow probes and intracerebroventricular guide tubes. Two hours after intracerebroventricular infusion of urotensin II ( 0.2 nmol/kg over 1 hour; n = 5), heart rate ( + 56 +/- 13 beats per minute [bpm]), dF/dt ( an index of cardiac contractility; + 533 +/- 128 L . min(-1) . s(-1)), and cardiac output ( + 3.4 +/- 0.4 L/min) increased significantly compared with vehicle, as did renal, mesenteric, and iliac blood flows and conductances. Plasma epinephrine, adrenocorticotropic hormone, and glucose levels also increased dramatically ( + 753 +/- 166 pg/mL, + 14.3 +/- 3.5 pmol/L, and + 7.0 +/- 1.4 mmol/L, respectively). All of these variables remained elevated for up to 4 hours after infusion. In contrast, 1 hour after intravenous urotensin II (40 nmol/kg bolus; n = 6), a sustained tachycardia ( + 25 +/- 8 bpm) ensued, but cardiac output, cardiac contractility, total peripheral conductance, and plasma glucose levels did not change significantly. In summary, this is the first study to show that urotensin II acts centrally to stimulate sympathoadrenal and pituitary-adrenal pathways, resulting in increased adrenocorticotropic hormone and epinephrine release and potent chronotropic and inotropic actions. In contrast, tachycardia was the only major response to intravenous urotensin II. These findings suggest that urotensin II is a novel stimulator of central pathways that mediate responses to alerting stimuli or stress.
引用
收藏
页码:373 / 379
页数:7
相关论文
共 34 条
  • [11] Congestive heart failure and expression of myocardial urotensin II
    Douglas, SA
    Tayara, L
    Ohlstein, EH
    Halawa, N
    Giaid, A
    [J]. LANCET, 2002, 359 (9322) : 1990 - 1997
  • [12] Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease
    Douglas, SA
    Ohlstein, EH
    [J]. TRENDS IN CARDIOVASCULAR MEDICINE, 2000, 10 (06) : 229 - 237
  • [13] Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey
    Douglas, SA
    Sulpizio, AC
    Piercy, V
    Sarau, HM
    Ames, RS
    Aiyar, NV
    Ohlstein, EH
    Willette, RN
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (07) : 1262 - 1274
  • [14] Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure
    Dschietzig, T
    Bartsch, C
    Pregla, R
    Zurbrügg, HR
    Armbruster, FP
    Richter, C
    Laule, M
    Romeyke, E
    Neubert, C
    Voelter, W
    Baumann, G
    Stangl, K
    [J]. REGULATORY PEPTIDES, 2002, 110 (01) : 33 - 38
  • [15] Urotensin II-immunoreactivity in the brainstem and spinal cord of the rat
    Dun, SL
    Brailoiu, GC
    Yang, J
    Chang, JK
    Dun, NJ
    [J]. NEUROSCIENCE LETTERS, 2001, 305 (01) : 9 - 12
  • [16] Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey
    Elshourbagy, NA
    Douglas, SA
    Shabon, U
    Harrison, S
    Duddy, G
    Sechler, JL
    Ao, ZH
    Maleeff, BE
    Naselsky, D
    Disa, J
    Aiyar, NV
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (01) : 9 - 22
  • [17] Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats
    Gardiner, SM
    March, JE
    Kemp, PA
    Davenport, AP
    Bennett, T
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (08) : 1625 - 1629
  • [18] Central effects of urotensin-II following ICV administration in rats
    Gartlon, J
    Parker, F
    Harrison, DC
    Douglas, SA
    Ashmeade, TE
    Riley, GJ
    Hughes, ZA
    Taylor, SG
    Munton, RP
    Hagan, JJ
    Hunter, JA
    Jones, DNC
    [J]. PSYCHOPHARMACOLOGY, 2001, 155 (04) : 426 - 433
  • [19] CARDIOVASCULAR EFFECTS OF UROTENSIN-II IN ANESTHETIZED AND PITHED RATS
    GIBSON, A
    WALLACE, P
    BERN, HA
    [J]. GENERAL AND COMPARATIVE ENDOCRINOLOGY, 1986, 64 (03) : 435 - 439
  • [20] COMPLEX EFFECTS OF GILLICHTHYS UROTENSIN-II ON RAT AORTIC STRIPS
    GIBSON, A
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1987, 91 (01) : 205 - 212